Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus

This publication has 35 references indexed in Scilit:

• Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of Action
  Antimicrobial Agents and Chemotherapy, 2002
• Benzimidazoles for the treatment of human cytomegalovirus: G. W. Koszalka, S. D. Chamberlain, R. J. Harvey, L. W. Frick, S. S. Good, M. L. Davis, A. Smith, J. C. Drach∗, L. B. Townsend∗, and K. K. Biron, Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA, ∗University of Michigan, Ann Arbor, MI 48109 USA
  Antiviral Research, 1996
• Design, Synthesis, and Antiviral Activity of Certain 2,5,6-Trihalo-1-(.beta.-D-ribofuranosyl)benzimidazoles
  Journal of Medicinal Chemistry, 1995
• Concurrent Use of Ganciclovir and Foscarnet to Treat Cytomegalovirus Infection in AIDS Patients
  The Journal of Infectious Diseases, 1993
• Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro
  European Journal of Clinical Microbiology & Infectious Diseases, 1992
• Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet
  The Lancet, 1991
• Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet
  The Lancet, 1991
• Foscarnet
  Drugs, 1991
• Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro
  Antiviral Research, 1990
• Foscarnet Nephrotoxicity: Mechanism, Incidence and Prevention
  American Journal of Nephrology, 1989